Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab monotherapy in advanced solid tumors
NCT02527434Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- Feb 2018
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 5
01
Overview
A Phase 2 trial of tremelimumab in Urothelial Bladder Cancer (UBC), triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), sponsored by AstraZeneca. Started Nov 2015; status: completed.
02
Drugs
tremelimumab
03
Conditions
Urothelial Bladder Cancer (UBC)triple-negative breast cancer (TNBC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02527434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02527434.